Literature DB >> 11406296

Amphetamine administration does not alter protein levels of the GLT-1 and EAAC1 glutamate transporter subtypes in rat midbrain, nucleus accumbens, striatum, or prefrontal cortex.

K Sidiropoulou1, S Chao, W Lu, M E Wolf.   

Abstract

Our laboratory and others have previously shown that glutamate transmission is required for chronic amphetamine-induced neuroadaptations, and that glutamate transmission itself is altered by chronic amphetamine administration. For example, N-methyl-D-aspartate (NMDA) and alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) receptor subunit expression are altered in a region- and withdrawal-specific manner. The goal of this study was to determine whether repeated amphetamine administration influences the expression of two glutamate transporter subtypes, GLT-1 and EAAC1. Rats were treated with saline or 5 mg/kg amphetamine for 5 days (chronic saline and amphetamine groups, respectively), or saline for 4 days and 5 mg/kg amphetamine on day 5 (acute amphetamine group), and decapitated 24 h after the last injection. Tissue was dissected from brain regions involved in the psychomotor effects of amphetamine (nucleus accumbens, striatum, prefrontal cortex, ventral tegmental area, and substantia nigra). Levels of GLT-1 and EAAC1 were quantified by Western blotting and normalized to actin levels. We found no significant change in levels of GLT-1 or EAAC1 in response to either acute or chronic amphetamine treatment. These findings suggest that the transporter component of the glutamate system might not play a significant role in the alterations in glutamate transmission observed following repeated amphetamine administration.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11406296     DOI: 10.1016/s0169-328x(01)00110-3

Source DB:  PubMed          Journal:  Brain Res Mol Brain Res        ISSN: 0169-328X


  11 in total

1.  Effects of Methamphetamine Self-Administration and Extinction on Astrocyte Structure and Function in the Nucleus Accumbens Core.

Authors:  B M Siemsen; C M Reichel; K C Leong; C Garcia-Keller; C D Gipson; S Spencer; J A McFaddin; K N Hooker; P W Kalivas; M D Scofield
Journal:  Neuroscience       Date:  2019-03-26       Impact factor: 3.590

2.  Dynamic interactions of ceftriaxone and environmental variables suppress amphetamine seeking.

Authors:  Erik J Garcia; David L Arndt; Mary E Cain
Journal:  Brain Res       Date:  2019-02-01       Impact factor: 3.252

Review 3.  Glutamate Transporter GLT-1 as a Therapeutic Target for Substance Use Disorders.

Authors:  Douglas J Roberts-Wolfe; Peter W Kalivas
Journal:  CNS Neurol Disord Drug Targets       Date:  2015       Impact factor: 4.388

Review 4.  Astrocyte regulation of synaptic signaling in psychiatric disorders.

Authors:  Anna Kruyer; Peter W Kalivas; Michael D Scofield
Journal:  Neuropsychopharmacology       Date:  2022-05-16       Impact factor: 7.853

Review 5.  Astrocyte Bioenergetics and Major Psychiatric Disorders.

Authors:  Ivan V Maly; Michael J Morales; Mikhail V Pletnikov
Journal:  Adv Neurobiol       Date:  2021

Review 6.  Methamphetamine Dysregulation of the Central Nervous System and Peripheral Immunity.

Authors:  Douglas R Miller; Mengfei Bu; Adithya Gopinath; Luis R Martinez; Habibeh Khoshbouei
Journal:  J Pharmacol Exp Ther       Date:  2021-09-17       Impact factor: 4.402

Review 7.  Glutamatergic substrates of drug addiction and alcoholism.

Authors:  Justin T Gass; M Foster Olive
Journal:  Biochem Pharmacol       Date:  2007-06-30       Impact factor: 5.858

Review 8.  Animal models and treatments for addiction and depression co-morbidity.

Authors:  Neil E Paterson; Athina Markou
Journal:  Neurotox Res       Date:  2007-01       Impact factor: 3.911

Review 9.  Glutamate Transport: A New Bench to Bedside Mechanism for Treating Drug Abuse.

Authors:  Sade Spencer; Peter W Kalivas
Journal:  Int J Neuropsychopharmacol       Date:  2017-10-01       Impact factor: 5.176

Review 10.  Astroglial correlates of neuropsychiatric disease: From astrocytopathy to astrogliosis.

Authors:  Ronald Kim; Kati L Healey; Marian T Sepulveda-Orengo; Kathryn J Reissner
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2017-10-06       Impact factor: 5.067

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.